Education
About Us
Working with TipRanks
Follow Us
Santen Pharmaceutical Co Ltd (SNPHF)
OTHER OTC:SNPHF
Total Valuation
Santen Pharmaceutical Co has a market cap or net worth of $3.63B. The enterprise value is $527.07B.
Market Cap$3.63B
Enterprise Value$527.07B
Share Statistics
Santen Pharmaceutical Co has 322,273,960 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding322,273,960
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Santen Pharmaceutical Co’s return on equity (ROE) is 0.13 and return on invested capital (ROIC) is 13.04%.
Return on Equity (ROE)0.13
Return on Assets (ROA)0.09
Return on Invested Capital (ROIC)13.04%
Return on Capital Employed (ROCE)0.17
Revenue Per Employee80.13M
Profits Per Employee9.68M
Employee Count3,744
Asset Turnover0.73
Inventory Turnover2.50
Valuation Ratios
The current PE Ratio of Santen Pharmaceutical Co is 18.5. Santen Pharmaceutical Co’s PEG ratio is 0.32.
PE Ratio18.5
PS Ratio1.65
PB Ratio1.73
Price to Fair Value1.73
Price to FCF9.11
Price to Operating Cash Flow―
PEG Ratio0.32
Income Statement
In the last 12 months, Santen Pharmaceutical Co had revenue of 300.00B and earned 36.25B in profits. Earnings per share was 103.98.
Revenue300.00B
Gross Profit171.03B
Operating Income56.23B
Pretax Income47.48B
Net Income36.25B
EBITDA68.83B
Earnings Per Share (EPS)103.98
Cash Flow
In the last 12 months, operating cash flow was 60.93B and capital expenditures -6.66B, giving a free cash flow of 54.27B billion.
Operating Cash Flow60.93B
Free Cash Flow54.27B
Free Cash Flow per Share168.38
Dividends & Yields
Santen Pharmaceutical Co pays an annual dividend of $0.123, resulting in a dividend yield of 2.47%
Dividend Per Share$0.123
Dividend Yield2.47%
Payout Ratio83.46%
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.11
52-Week Price Change27.47%
50-Day Moving Average10.59
200-Day Moving Average10.71
Relative Strength Index (RSI)60.12
Average Volume (3m)0.00
Important Dates
Santen Pharmaceutical Co upcoming earnings date is May 12, 2026, TBA (Confirmed).
Last Earnings DateFeb 5, 2026
Next Earnings DateMay 12, 2026
Ex-Dividend Date―
Financial Position
Santen Pharmaceutical Co as a current ratio of 2.58, with Debt / Equity ratio of ―
Current Ratio2.58
Quick Ratio1.99
Debt to Market Cap0.06
Net Debt to EBITDA-0.85
Interest Coverage Ratio20.70
Taxes
In the past 12 months, Santen Pharmaceutical Co has paid 11.63B in taxes.
Income Tax11.63B
Effective Tax Rate0.24
Enterprise Valuation
Santen Pharmaceutical Co EV to EBITDA ratio is 6.33, with an EV/FCF ratio of 8.03.
EV to Sales1.45
EV to EBITDA6.33
EV to Free Cash Flow8.03
EV to Operating Cash Flow7.15
Balance Sheet
Santen Pharmaceutical Co has $93.00B in cash and marketable securities with $36.15B in debt, giving a net cash position of $58.77B billion.
Cash & Marketable Securities$93.00B
Total Debt$36.15B
Net Cash$58.77B
Net Cash Per Share$182.35
Tangible Book Value Per Share$601.58
Margins
Gross margin is ―, with operating margin of 18.74%, and net profit margin of 12.08%.
Gross Margin―
Operating Margin18.74%
Pretax Margin15.83%
Net Profit Margin12.08%
EBITDA Margin22.94%
EBIT Margin16.96%
Analyst Forecast
The average price target for Santen Pharmaceutical Co is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast―